Gut Flora Atlas
IndexT Published Reading timeReading time: 5 min

The Microbiome in Multiple Sclerosis Etiology

By Gut Flora Atlas Editorial team · Updated

Insulated copper cables, one with frayed outer coating, near wooden beads and plant shoots.
Gut bacteria are studied for their potential link to nerve sheath integrity. Illustration: AI-generated

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by immune-mediated demyelination and neurodegeneration. While genetic predisposition and environmental factors have long been recognized as contributors to MS development, emerging research increasingly implicates the gut microbiome as a significant player in disease etiology. The composition, diversity, and functional capacity of microbial communities in the gastrointestinal tract appear to influence immune tolerance mechanisms and systemic inflammation, potentially modulating MS risk and progression. This article examines the current understanding of how microbiota alterations may contribute to multiple sclerosis pathogenesis.

Dysbiosis and Immune Dysregulation in MS

Dysbiosis, defined as alterations in the composition and diversity of microbial communities, has been reported in individuals with multiple sclerosis compared to healthy controls, although specific findings vary between studies. Several studies have identified reduced microbial diversity and shifts in dominant bacterial phyla in MS patients, with particular reductions in Faecalibacterium prausnitzii and other short-chain fatty acid (SCFA)-producing bacteria. These compositional changes correlate with altered immune responses, suggesting a mechanistic link between dysbiotic states and disease pathology.

The mechanisms underlying this connection involve disrupted intestinal barrier function and aberrant T cell differentiation. A dysbiotic microbiota may fail to adequately support the microbiome's role in oral tolerance development, a critical process for maintaining immune homeostasis. Reduced production of immunoregulatory metabolites by dysbiotic communities can lead to decreased differentiation of regulatory T cells (Tregs), which normally suppress autoreactive immune responses. Conversely, dysbiosis may promote the expansion of pro-inflammatory Th17 cells, which produce interleukin-17 and are implicated in MS pathogenesis. This shift in the Th17/Treg balance is a proposed mechanism through which microbiota composition may influence MS risk.

Additionally, dysbiosis may be accompanied by increased intestinal permeability, sometimes referred to as "leaky gut." Compromised epithelial barrier integrity allows bacterial lipopolysaccharides (LPS) and other pathogen-associated molecular patterns to translocate across the intestinal epithelium, triggering systemic immune activation. This phenomenon is particularly relevant to MS, as increased translocation of microbial antigens may promote cross-reactive immune responses against myelin antigens in the central nervous system.

Microbial Metabolites and Neuroinflammation

Beyond compositional changes, the functional output of the microbiota, particularly the production of microbial metabolites, plays a crucial role in MS etiology. Short-chain fatty acids, especially butyrate, are produced through bacterial fermentation of dietary fiber and exert potent immunomodulatory effects. Butyrate serves as a histone deacetylase (HDAC) inhibitor, promoting Treg differentiation and enhancing intestinal barrier function through effects on tight junction proteins. Reduced SCFA-producing capacity in dysbiotic MS microbiota may therefore contribute to increased intestinal permeability and reduced immune tolerance.

The role of microbial metabolic byproducts and systemic effects extends beyond SCFA production. Other bacterial metabolites, including secondary bile acids, tryptophan metabolites, and lipopolysaccharides, modulate immune responses through pattern recognition receptors and G protein-coupled receptors. Alterations in the production of these signaling molecules by dysbiotic communities may shift immune responses toward pro-inflammatory states characteristic of MS. Furthermore, microbial signaling molecules and host recognition mechanisms are fundamental to how the immune system interprets microbial community composition, making dysbiosis-associated changes in metabolite profiles particularly significant for disease pathogenesis.

Molecular Mimicry and Antigen Cross-Reactivity

Another proposed mechanism linking dysbiosis to MS involves molecular mimicry between microbial antigens and central nervous system autoantigens. Some microbial antigens have been proposed to share structural similarity with myelin oligodendrocyte glycoprotein (MOG) and other myelin proteins. The best-documented example in MS involves a viral rather than bacterial antigen: antibodies against the Epstein-Barr virus protein EBNA1 can cross-react with the CNS protein GlialCAM. Dysbiotic shifts that increase the abundance of such cross-reactive bacteria may promote the expansion of autoreactive T and B cells capable of targeting myelin antigens. This mechanism is supported by observations that some MS patients demonstrate antibody and T cell responses cross-reactive with both microbial and myelin antigens.

The composition of the microbiota during critical developmental windows may also be relevant. Early-life microbiota establishment influences immune system maturation and tolerance development, and disruptions during this period may increase MS susceptibility later in life. This developmental aspect underscores the importance of microbiota stability across the lifespan in maintaining immune homeostasis.

Mechanisms

Proposed routes from gut microbiota to MS

  • Immune balanceDysbiosis may shift the balance away from regulatory T cells toward pro-inflammatory Th17 cells.
  • Fewer SCFA producersLower butyrate output may weaken barrier function and immune tolerance.
  • Barrier permeabilityTranslocated bacterial components such as LPS may drive systemic immune activation.
  • Molecular mimicrySome microbial epitopes resemble myelin proteins and may expand cross-reactive T and B cells.
  • Early-life windowDisrupted microbiota development may affect immune maturation and later susceptibility.
Summarized from this article. These are proposed mechanisms. Causal evidence comes mainly from mouse models (EAE); human case-control studies show varying effect sizes. General information only, not a diagnosis or treatment advice.

Scientific Background

The investigation of microbiota involvement in MS etiology employs multiple methodological approaches, including 16S ribosomal RNA gene sequencing for taxonomic profiling, metagenomic sequencing for functional gene analysis, and metabolomic approaches to quantify microbial metabolite production. Animal models, particularly mice with experimental autoimmune encephalomyelitis (EAE), have demonstrated that microbiota composition directly influences disease susceptibility and severity. Germ-free mice and antibiotic-treated mice show altered EAE phenotypes, providing causal evidence for microbiota involvement in this animal model. Clinical studies comparing MS patients with matched controls have consistently identified dysbiotic patterns, though effect sizes vary across populations and studies, suggesting heterogeneity in microbiota-MS relationships.

Conclusion

The microbiome is increasingly considered a possible contributor to MS etiology, operating through multiple interconnected mechanisms including immune tolerance dysregulation, altered metabolite production, intestinal barrier dysfunction, and molecular mimicry. Microbiota alterations reported in MS patients, including changes in composition and metabolic capacity, may contribute to pro-inflammatory immune states. Future research should focus on characterizing the temporal relationship between dysbiosis and MS onset, identifying specific dysbiosis signatures predictive of disease progression, and evaluating whether microbiota-targeted interventions can modify MS outcomes. Understanding the microbiome's role in MS pathogenesis may reveal novel therapeutic targets and inform preventive strategies for at-risk populations.

This article is for general information and does not replace professional advice, diagnosis or treatment.

See also

TSeptember 2026

The Microbiome and Metabolic Endotoxemia Mechanisms

Metabolic endotoxemia describes low, chronic levels of bacterial LPS in the blood. How it may arise, how it is measured and what the human evidence shows.

Reading time: 5 min

TAugust 2026

The Microbiome's Role in Oral Tolerance Development

Oral tolerance represents a fundamental immunological mechanism that enables the gastrointestinal tract to maintain a state of immune non-responsiveness toward harmless dietary antigens and …

Reading time: 5 min

TJuly 2026

The Microbiome and Migraine Pathophysiology

Migraine affects an estimated one billion people worldwide, making it one of the most prevalent neurological disorders. While traditional research has focused on vascular and neurological …

Reading time: 5 min